Hemato Oncology Testing Market Trends

Innovations in molecular diagnostic technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH), have improved the accuracy and speed of hemato oncology testing, driving market growth during the analysis period. For example, the National Comprehensive Cancer Network and the European LeukemiaNet guidelines for chronic myelogenous leukemia (CML) endorse the RT-qPCR test for diagnosis confirmation. They recommend the RT-qPCR test every 3 months until BCR-ABL1 transcripts drop below 0.1%, then every 3 to 6 months. This increases the use of PCR-based assays, given their high sensitivity in detecting genetic mutations in patient blood samples and bone marrow. Furthermore, advancements in diagnostic technology facilitate personalized medicine approaches, increasing the demand for hemato-oncology testing and contributing to market growth.